Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 Jan 27.
View in:
PubMed
Lower Incidence of Chronic GVHD Observed after Transplantation with Cryopreserved Unrelated Allogeneic Stem Cells. Blood Adv. 2023 Jan 03.
View in:
PubMed
A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022 11 08; 6(21):5786-5796.
View in:
PubMed
Ipilimumab plus decitabine for patients with MDS or AML in post-transplant or transplant naïve settings. Blood. 2022 Nov 04.
View in:
PubMed
Chronic GvHD NIH Consensus Project Biology Task Force: Evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022 Nov 02.
View in:
PubMed
Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica. 2022 11 01; 107(11):2617-2629.
View in:
PubMed
Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease. Front Immunol. 2022; 13:954966.
View in:
PubMed
Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022 08 09; 6(15):4392-4402.
View in:
PubMed
Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022 06 16; 139(24):3546-3557.
View in:
PubMed
Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022 06 21; 119(25):e2122379119.
View in:
PubMed
Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11).
View in:
PubMed
BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997.
View in:
PubMed
GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194.
View in:
PubMed
Microbiota dynamics in a randomized trial of gut decontamination during allogeneic hematopoietic cell transplantation. JCI Insight. 2022 04 08; 7(7).
View in:
PubMed
[First 18 months as certified ERAS® center for colorectal cancer : Lessons learned and results of the first 261 patients]. Chirurgie (Heidelb). 2022 Jul; 93(7):687-693.
View in:
PubMed
Cell-free DNA profiling informs all major complications of hematopoietic cell transplantation. Proc Natl Acad Sci U S A. 2022 01 25; 119(4).
View in:
PubMed
Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149.
View in:
PubMed
Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222.
View in:
PubMed
Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2022 01 10; 40(2):189-201.
View in:
PubMed
Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992.
View in:
PubMed
Author Correction: Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 Nov; 22(11):1465.
View in:
PubMed
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma. Transplant Cell Ther. 2022 01; 28(1):32.e1-32.e10.
View in:
PubMed
Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunol Res. 2021 12; 9(12):1465-1475.
View in:
PubMed
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217.
View in:
PubMed
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseases. J Transl Autoimmun. 2021; 4:100103.
View in:
PubMed
Blockade of IL-22 signaling reverses erythroid dysfunction in stress-induced anemias. Nat Immunol. 2021 04; 22(4):520-529.
View in:
PubMed
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2020 Etiology and Prevention Working Group Report. Transplant Cell Ther. 2021 06; 27(6):452-466.
View in:
PubMed
Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. Front Immunol. 2020; 11:608485.
View in:
PubMed
Comparative analysis of cell therapy infusion workflows at clinical sites. Cytotherapy. 2021 04; 23(4):285-292.
View in:
PubMed
Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364.
View in:
PubMed
Maturation and Phenotypic Heterogeneity of Human CD4+ Regulatory T Cells From Birth to Adulthood and After Allogeneic Stem Cell Transplantation. Front Immunol. 2020; 11:570550.
View in:
PubMed
Cell-free DNA tissues of origin by methylation profiling reveals significant cell, tissue, and organ-specific injury related to COVID-19 severity. Med (N Y). 2021 04 09; 2(4):411-422.e5.
View in:
PubMed
Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature. 2021 02; 590(7844):157-162.
View in:
PubMed
Chimeric Antigen Receptor T Cells Targeting NKG2D-Ligands Show Robust Efficacy Against Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia. Front Immunol. 2020; 11:580328.
View in:
PubMed
Post-Transcriptional Genetic Silencing of BCL11A to Treat Sickle Cell Disease. N Engl J Med. 2021 01 21; 384(3):205-215.
View in:
PubMed
Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561).
View in:
PubMed
Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123.
View in:
PubMed
Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636.
View in:
PubMed
Cell-Free DNA in Blood Reveals Significant Cell, Tissue and Organ Specific injury and Predicts COVID-19 Severity. medRxiv. 2020 Jul 29.
View in:
PubMed
Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. J Clin Oncol. 2020 09 20; 38(27):3095-3106.
View in:
PubMed
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
View in:
PubMed
A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191.
View in:
PubMed
T Cell Clonal Dynamics Determined by High-Resolution TCR-ß Sequencing in Recipients after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 09; 26(9):1567-1574.
View in:
PubMed
Personalized iPSC-Derived Dopamine Progenitor Cells for Parkinson's Disease. N Engl J Med. 2020 05 14; 382(20):1926-1932.
View in:
PubMed
BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893.
View in:
PubMed
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv. 2020 01 14; 4(1):122-126.
View in:
PubMed
Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40.
View in:
PubMed
A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810.
View in:
PubMed
Assessment of a multi-cytokine profile by a novel biochip-based assay allows correlation of cytokine profiles with clinical outcomes in adult recipients of umbilical cord blood transplantation. Bone Marrow Transplant. 2020 09; 55(9):1821-1823.
View in:
PubMed
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561.
View in:
PubMed
Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation. Clin Hematol Int. 2019 Dec; 1(4):201-204.
View in:
PubMed
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204.
View in:
PubMed
Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151.
View in:
PubMed
Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. Clin Immunol. 2019 10; 207:18-23.
View in:
PubMed
Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979.
View in:
PubMed
Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994.
View in:
PubMed
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood. 2019 07 04; 134(1):22-29.
View in:
PubMed
Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830.
View in:
PubMed
Clinical Metabolomics Identifies Blood Serum Branched Chain Amino Acids as Potential Predictive Biomarkers for Chronic Graft vs. Host Disease. Front Oncol. 2019; 9:141.
View in:
PubMed
Naive and Stem Cell Memory T Cell Subset Recovery Reveals Opposing Reconstitution Patterns in CD4 and CD8 T Cells in Chronic Graft vs. Host Disease. Front Immunol. 2019; 10:334.
View in:
PubMed
A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica. 2019 07; 104(7):e314-e317.
View in:
PubMed
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019 01; 565(7738):234-239.
View in:
PubMed
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112.
View in:
PubMed
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99.
View in:
PubMed
Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant. 2018 11; 24(11):2216-2223.
View in:
PubMed
Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy. Cytotherapy. 2018 07; 20(7):952-963.
View in:
PubMed
NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv. 2018 06 26; 2(12):1412-1416.
View in:
PubMed
Biomanufacturing for clinically advanced cell therapies. Nat Biomed Eng. 2018 06; 2(6):362-376.
View in:
PubMed
Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353.
View in:
PubMed
A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740.
View in:
PubMed
Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2018 03 14; 555(7696):402.
View in:
PubMed
Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530.
View in:
PubMed
Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. J Neurooncol. 2018 Apr; 137(2):269-278.
View in:
PubMed
Signaling by the Epstein-Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc Natl Acad Sci U S A. 2018 01 23; 115(4):E686-E695.
View in:
PubMed
Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279.
View in:
PubMed
Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899.
View in:
PubMed
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation. Cancer Discov. 2018 02; 8(2):216-233.
View in:
PubMed
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011.
View in:
PubMed
An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017 07 13; 547(7662):217-221.
View in:
PubMed
An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12).
View in:
PubMed
Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017 06 15; 129(24):3256-3261.
View in:
PubMed
Research Techniques Made Simple: Mass Cytometry Analysis Tools for Decrypting the Complexity of Biological Systems. J Invest Dermatol. 2017 05; 137(5):e43-e51.
View in:
PubMed
Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94.
View in:
PubMed
Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. Cancer Discov. 2017 08; 7(8):852-867.
View in:
PubMed
Research Techniques Made Simple: Experimental Methodology for Single-Cell Mass Cytometry. J Invest Dermatol. 2017 04; 137(4):e31-e38.
View in:
PubMed
Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-ß production. Blood. 2017 05 04; 129(18):2570-2580.
View in:
PubMed
Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer. 2017 Jul 15; 123(14):2642-2650.
View in:
PubMed
Adoptive Transfer of Invariant NKT Cells as Immunotherapy for Advanced Melanoma: A Phase I Clinical Trial. Clin Cancer Res. 2017 Jul 15; 23(14):3510-3519.
View in:
PubMed
PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197.
View in:
PubMed
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388.
View in:
PubMed
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605.
View in:
PubMed
Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284.
View in:
PubMed
Mechanistic approaches for the prevention and treatment of chronic GVHD. Blood. 2017 01 05; 129(1):22-29.
View in:
PubMed
Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278.
View in:
PubMed
Risk factors for reoperation after ileostomy reversal - Results from a prospective cohort study. Int J Surg. 2016 Dec; 36(Pt A):233-239.
View in:
PubMed
Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. Biol Blood Marrow Transplant. 2017 01; 23(1):103-112.
View in:
PubMed
Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850.
View in:
PubMed
The Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2017 Feb; 23(2):211-234.
View in:
PubMed
CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. Immunity. 2016 07 19; 45(1):209-23.
View in:
PubMed
Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183.
View in:
PubMed
Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7.
View in:
PubMed
A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259.
View in:
PubMed
Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016 07 14; 128(2):195-203.
View in:
PubMed
Necessity of subcutaneous suction drains in ileostomy reversal (DRASTAR)-a randomized, controlled bi-centered trial. Langenbecks Arch Surg. 2016 Jun; 401(4):409-18.
View in:
PubMed
Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7.
View in:
PubMed
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586.
View in:
PubMed
Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 04 28; 127(17):2144-54.
View in:
PubMed
Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97.
View in:
PubMed
Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway. Cancer Immunol Immunother. 2016 Mar; 65(3):355-66.
View in:
PubMed
Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505.
View in:
PubMed
Dramatic Expansion of HSCs: New Possibilities for HSC Transplants? Cell Stem Cell. 2016 Jan 07; 18(1):10-2.
View in:
PubMed
Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57.
View in:
PubMed
Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica. 2016 Jan; 101(1):e30-3.
View in:
PubMed
IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. PLoS One. 2015; 10(7):e0132564.
View in:
PubMed
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13.
View in:
PubMed
Reconstitution of T Cell Immunity after Umbilical Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015 Jul; 21(7):1151-2.
View in:
PubMed
Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94.
View in:
PubMed
Biologic Activity of Autologous, Granulocyte-Macrophage Colony-Stimulating Factor Secreting Alveolar Soft-Part Sarcoma and Clear Cell Sarcoma Vaccines. Clin Cancer Res. 2015 Jul 15; 21(14):3178-86.
View in:
PubMed
Interferon-?-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology. 2015 Jun; 4(6):e1008824.
View in:
PubMed
Aberrant B-cell homeostasis in chronic GVHD. Blood. 2015 Mar 12; 125(11):1703-7.
View in:
PubMed
Reprint of: B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Feb; 21(2 Suppl):S11-8.
View in:
PubMed
Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80.
View in:
PubMed
Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8.
View in:
PubMed
B cells in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2015 Jan; 21(1):16-23.
View in:
PubMed
A modified ?-retrovirus vector for X-linked severe combined immunodeficiency. N Engl J Med. 2014 Oct 09; 371(15):1407-17.
View in:
PubMed
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76.
View in:
PubMed
Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6.
View in:
PubMed
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8.
View in:
PubMed
A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43.
View in:
PubMed
Current issues in chronic graft-versus-host disease. Blood. 2014 Jul 17; 124(3):374-84.
View in:
PubMed
Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21.
View in:
PubMed
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood. 2014 Jul 17; 124(3):453-62.
View in:
PubMed
Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508.
View in:
PubMed
Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98.
View in:
PubMed
White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7.
View in:
PubMed
Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9.
View in:
PubMed
Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target. Exp Hematol. 2014 Apr; 42(4):307-316.e8.
View in:
PubMed
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75.
View in:
PubMed
Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21.
View in:
PubMed
Tregs, HSCT, and acute GVHD: up close and personal. Blood. 2013 Sep 05; 122(10):1690-1.
View in:
PubMed
Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81.
View in:
PubMed
ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death. N Engl J Med. 2013 Aug 08; 369(6):529-39.
View in:
PubMed
Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65.
View in:
PubMed
[What is the actual benefit of sigmoid resection for acute diverticulitis? : Functional outcome after surgical and conservative treatment]. Chirurg. 2013 Aug; 84(8):673-80.
View in:
PubMed
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7.
View in:
PubMed
A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica. 2013 Jun; 98(6):964-70.
View in:
PubMed
Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43.
View in:
PubMed
Identification of cytolytic CD161- CD56+ regulatory CD8 T cells in human peripheral blood. PLoS One. 2013; 8(3):e59545.
View in:
PubMed
Probing circulating tumor cells in microfluidics. Lab Chip. 2013 Feb 21; 13(4):602-9.
View in:
PubMed
Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11.
View in:
PubMed
Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83.
View in:
PubMed
Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of T-cell response to K562 cell antigens in CML patients. Oncoimmunology. 2012 Oct 01; 1(7):1095-1103.
View in:
PubMed
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012 Sep 20; 120(12):2529-36.
View in:
PubMed
Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8.
View in:
PubMed
A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13.
View in:
PubMed
Tyrosine kinase pathways modulate tumor susceptibility to natural killer cells. J Clin Invest. 2012 Jul; 122(7):2369-83.
View in:
PubMed
Expression of CD30 in patients with acute graft-versus-host disease. Blood. 2012 Jul 19; 120(3):691-6.
View in:
PubMed
Development and implementation of a computerized system for collection, processing, and administration of cellular therapy products. J Oncol Pract. 2012 Sep; 8(5):262-6.
View in:
PubMed
Reduction of wound infections in laparoscopic-assisted colorectal resections by plastic wound ring drapes (REDWIL)?--A randomized controlled trial. Langenbecks Arch Surg. 2012 Oct; 397(7):1079-85.
View in:
PubMed
Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
View in:
PubMed
Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66.
View in:
PubMed
A clonal model for human CD8+ regulatory T cells: unrestricted contact-dependent killing of activated CD4+ T cells. Eur J Immunol. 2012 Jan; 42(1):69-79.
View in:
PubMed
Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood. 2012 Feb 09; 119(6):1570-80.
View in:
PubMed
Time to put the CAR-T before the horse. Blood. 2011 Nov 03; 118(18):4761-2.
View in:
PubMed
Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12.
View in:
PubMed
Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7.
View in:
PubMed
Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30.
View in:
PubMed
Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74.
View in:
PubMed
Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65.
View in:
PubMed
[Acute sigmoid diverticulitis. Are operations more frequent since the introduction of laparoscopy and CT scanning?]. Chirurg. 2011 Aug; 82(8):701-6.
View in:
PubMed
Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84.
View in:
PubMed
MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. PLoS One. 2011 Mar 08; 6(3):e16956.
View in:
PubMed
Viral induction and targeted inhibition of galectin-1 in EBV+ posttransplant lymphoproliferative disorders. Blood. 2011 Apr 21; 117(16):4315-22.
View in:
PubMed
The elusive nature and function of mesenchymal stem cells. Nat Rev Mol Cell Biol. 2011 02; 12(2):126-31.
View in:
PubMed
Preclinical regulatory validation of an engineered diaphragmatic tendon made with amniotic mesenchymal stem cells. J Pediatr Surg. 2011 Jan; 46(1):57-61.
View in:
PubMed
Validation of short-term handling and storage conditions for marrow and peripheral blood stem cell products. Transfusion. 2011 Jan; 51(1):137-47.
View in:
PubMed
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204.
View in:
PubMed
Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71.
View in:
PubMed
Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83.
View in:
PubMed
B-cell-directed therapy for chronic graft-versus-host disease. Haematologica. 2010 Nov; 95(11):1811-3.
View in:
PubMed
Predictors of permanent ileostomy after restorative proctocolectomy. Br J Surg. 2010 Oct; 97(10):1561-6.
View in:
PubMed
Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39.
View in:
PubMed
Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93.
View in:
PubMed
Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5.
View in:
PubMed
Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51.
View in:
PubMed
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant. 2010 May; 16(5):565-86.
View in:
PubMed
Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55.
View in:
PubMed
Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9.
View in:
PubMed
Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15.
View in:
PubMed
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800.
View in:
PubMed
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
View in:
PubMed
Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4.
View in:
PubMed
Current challenges in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2010 Jan; 16(1 Suppl):S146-51.
View in:
PubMed
Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning. J Allergy Clin Immunol. 2009 Nov; 124(5):1062-9.e1-4.
View in:
PubMed
[Laparoscopic appendectomy: is it worth the cost?]. Chirurg. 2009 Oct; 80(10):966-8.
View in:
PubMed
Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9.
View in:
PubMed
Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30.
View in:
PubMed
[Therapy of refractory proctocolitis and Crohn's disease. Incisionless laparoscopic proctocolectomy with a Brooke ileostomy]. Chirurg. 2009 Aug; 80(8):730-3.
View in:
PubMed
Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76.
View in:
PubMed
Revealing tumor immunity after hematopoietic stem cell transplantation. Clin Cancer Res. 2009 Jul 15; 15(14):4515-7.
View in:
PubMed
Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Mar; 15(3):382-8.
View in:
PubMed
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74.
View in:
PubMed
Long-term outcomes of nonconditioned patients with severe combined immunodeficiency transplanted with HLA-identical or haploidentical bone marrow depleted of T cells with anti-CD6 mAb. J Allergy Clin Immunol. 2008 Dec; 122(6):1185-93.
View in:
PubMed
Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8.
View in:
PubMed
Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7.
View in:
PubMed
Targets of tumor immunity after allogeneic hematopoietic stem cell transplantation. Clin Cancer Res. 2008 Aug 15; 14(16):4997-9.
View in:
PubMed
Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. Exp Hematol. 2008 Sep; 36(9):1205-15.
View in:
PubMed
Preclinical regulatory validation of a 3-stage amniotic mesenchymal stem cell manufacturing protocol. J Pediatr Surg. 2008 Jun; 43(6):1164-9.
View in:
PubMed
MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
View in:
PubMed
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35.
View in:
PubMed
Mixed haematopoietic chimerism for sickle cell disease prevents intravascular haemolysis. Br J Haematol. 2007 Nov; 139(3):504-7.
View in:
PubMed
High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14.
View in:
PubMed
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis. Haematologica. 2007 May; 92(5):619-26.
View in:
PubMed
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64.
View in:
PubMed
Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7.
View in:
PubMed
Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64.
View in:
PubMed
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55.
View in:
PubMed
Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation. Blood. 2007 Feb 15; 109(4):1355-62.
View in:
PubMed
Studying human regulatory T cells in vivo. Clin Cancer Res. 2006 Sep 15; 12(18):5265-7.
View in:
PubMed
SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood. 2006 Oct 15; 108(8):2726-35.
View in:
PubMed
IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9.
View in:
PubMed
Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62.
View in:
PubMed
CD34+CD38- and CD34+HLA-DR- cells in bone marrow stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologus transplantation. Cytotherapy. 2006; 8:399-407.
Induction of tumor immunity following allogeneic stem cell transplantation. Adv Immunol. 2006; 90:133-73.
View in:
PubMed
Gene expression profiles of B-lineage adult acute lymphocytic leukemia reveal genetic patterns that identify lineage derivation and distinct mechanisms of transformation. Clin Cancer Res. 2005 Oct 15; 11(20):7209-19.
View in:
PubMed
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. Blood. 2006 Jan 01; 107(1):197-204.
View in:
PubMed
Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96.
View in:
PubMed
Evidence for ineffective erythropoiesis in severe sickle cell disease. Blood. 2005 Nov 15; 106(10):3639-45.
View in:
PubMed
FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br J Haematol. 2005 Jul; 130(1):43-50.
View in:
PubMed
Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11.
View in:
PubMed
Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11.
View in:
PubMed
Genomic analysis in lymphoid leukemias. Rev Clin Exp Hematol. 2005 Jun 01; 9(1):E3.
View in:
PubMed
Bayesian error-in-variable survival model for the analysis of GeneChip arrays. Biometrics. 2005 Jun; 61(2):488-97.
View in:
PubMed
Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
View in:
PubMed
Immune reconstitution after allogeneic stem cell transplantation. Haematologica. 2005 Jan; 90(1):5.
View in:
PubMed
Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8.
View in:
PubMed
Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4.
View in:
PubMed
Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71.
View in:
PubMed
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6.
View in:
PubMed
Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42.
View in:
PubMed
Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61.
View in:
PubMed
A novel mechanism of alternative promoter and splicing regulates the epitope generation of tumor antigen CML66-L. J Immunol. 2004 Jan 01; 172(1):651-60.
View in:
PubMed
Imatinib therapy for patients with chronic myelogenous leukemia: are patients living longer? Clin Cancer Res. 2004 Jan 01; 10(1 Pt 1):1-3.
View in:
PubMed
Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood. 2004 Apr 01; 103(7):2771-8.
View in:
PubMed
Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; 32(12):1145-51.
View in:
PubMed
Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
View in:
PubMed
Molecular assessment of erythroid lineage chimerism following nonmyeloablative allogeneic stem cell transplantation. Exp Hematol. 2003 Oct; 31(10):924-33.
View in:
PubMed
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9.
View in:
PubMed
Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003 May 15; 63(10):2561-8.
View in:
PubMed
Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion. 2003 May; 43(5):614-21.
View in:
PubMed
Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9.
View in:
PubMed
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522.
View in:
PubMed
Allogeneic stem cell transplantation for multiple myeloma. Rev Clin Exp Hematol. 2002 Sep; 6(3):205-24.
View in:
PubMed
A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9.
View in:
PubMed
Adult hematopoietic stem cell plasticity. Transfusion. 2002 Aug; 42(8):1096-101.
View in:
PubMed
Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002 Jul; 8(7):2052-60.
View in:
PubMed
Human acute stem cell leukemia with multilineage differentiation potential via cascade activation of growth factor receptors. Blood. 2002 Jun 15; 99(12):4634-7.
View in:
PubMed
Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
View in:
PubMed
Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34.
View in:
PubMed
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24.
View in:
PubMed
Synergistic enhancement of cell-mediated immunity by interleukin-12 plus interleukin-2: basis for therapy of cutaneous T cell lymphoma. J Invest Dermatol. 2002 Feb; 118(2):366-71.
View in:
PubMed
Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44.
View in:
PubMed
Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32.
View in:
PubMed
T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001 Aug 15; 98(4):934-9.
View in:
PubMed
Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21.
View in:
PubMed
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7.
View in:
PubMed
Specific down-regulation of interleukin-12 signaling through induction of phospho-STAT4 protein degradation. Blood. 2001 Jun 15; 97(12):3860-6.
View in:
PubMed
A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7.
View in:
PubMed
CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9.
View in:
PubMed
CD2 stimulation leads to the delayed and prolonged activation of STAT1 in T cells but not NK cells. Exp Hematol. 2001 Feb; 29(2):209-20.
View in:
PubMed
MR-guided interstitial laser-induced thermotherapy of hepatic metastasis combined with arterial blood flow reduction: technique and first clinical results in an open MR system. J Magn Reson Imaging. 2001 Jan; 13(1):31-6.
View in:
PubMed
Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14.
View in:
PubMed
Interleukin-2 enhances the response of natural killer cells to interleukin-12 through up-regulation of the interleukin-12 receptor and STAT4. Blood. 2000 May 15; 95(10):3183-90.
View in:
PubMed
Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32.
View in:
PubMed
[Laser-induced thermotherapy (LITT) for liver metastasis in an open 0.2T MRI]. Rofo. 2000 Feb; 172(2):175-8.
View in:
PubMed
Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9.
View in:
PubMed
Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(4):375-86.
View in:
PubMed
Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33.
View in:
PubMed
Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35.
View in:
PubMed
CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor. Immunology. 1999 May; 97(1):159-65.
View in:
PubMed
The functional synergy between IL-12 and IL-2 involves p38 mitogen-activated protein kinase and is associated with the augmentation of STAT serine phosphorylation. J Immunol. 1999 Apr 15; 162(8):4472-81.
View in:
PubMed
Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat Med. 1999 Apr; 5(4):444-7.
View in:
PubMed
PTEN is inversely correlated with the cell survival factor Akt/PKB and is inactivated via multiple mechanismsin haematological malignancies. Hum Mol Genet. 1999 Feb; 8(2):185-93.
View in:
PubMed
Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8.
View in:
PubMed
IL-2 induces STAT4 activation in primary NK cells and NK cell lines, but not in T cells. J Immunol. 1999 Jan 01; 162(1):299-304.
View in:
PubMed
Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer. Clin Cancer Res. 1999 Jan; 5(1):9-16.
View in:
PubMed
Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8.
View in:
PubMed
Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998 Oct 15; 92(8):2725-9.
View in:
PubMed
Regulatory dysfunction of the interleukin-2 receptor during HIV infection and the impact of triple combination therapy. Proc Natl Acad Sci U S A. 1998 Sep 15; 95(19):11348-53.
View in:
PubMed
Dysregulation of interleukin-2 receptor beta and interleukin-2 receptor gamma expression during HIV infection. Eur Cytokine Netw. 1998 Sep; 9(3 Suppl):97-101.
View in:
PubMed
Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. J Clin Invest. 1998 Aug 01; 102(3):561-75.
View in:
PubMed
TAL1 expression does not occur in the majority of T-ALL blasts. Br J Haematol. 1998 Jul; 102(2):449-57.
View in:
PubMed
CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81.
View in:
PubMed
Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80.
View in:
PubMed
IL-15 is produced by a subset of human melanomas, and is involved in the regulation of markers of melanoma progression through juxtacrine loops. Oncogene. 1998 May 14; 16(19):2503-12.
View in:
PubMed
Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood. 1998 Feb 15; 91(4):1341-54.
View in:
PubMed
Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998 Feb 15; 160(4):1618-26.
View in:
PubMed
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8.
View in:
PubMed
Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998; 13(4):164-8.
View in:
PubMed
Further analysis of interleukin-2 receptor subunit expression on the different human peripheral blood mononuclear cell subsets. Blood. 1998 Jan 01; 91(1):165-72.
View in:
PubMed
Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001.
View in:
PubMed
B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest. 1997 Dec 15; 100(12):3140-8.
View in:
PubMed
Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. Blood. 1997 Nov 15; 90(10):4222-9.
View in:
PubMed
In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Nov; 3(5):267-72.
View in:
PubMed
Autologous versus unrelated donor allogeneic marrow transplantation for acute lymphoblastic leukemia. Blood. 1997 Oct 15; 90(8):2962-8.
View in:
PubMed
Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol. 1997 Sep 15; 159(6):3057-67.
View in:
PubMed
CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J Immunol. 1997 Sep 01; 159(5):2154-60.
View in:
PubMed
Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997 Aug 15; 100(4):855-66.
View in:
PubMed
Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol. 1997 May; 97(2):409-17.
View in:
PubMed
CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47.
View in:
PubMed
CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7.
View in:
PubMed
Expression of the IL-2 receptor gamma subunit in resting human CD4 T lymphocytes: mRNA is constitutively transcribed and the protein stored as an intracellular component. Int Immunol. 1997 Apr; 9(4):573-80.
View in:
PubMed
Interferon-gamma and interleukin-4 regulate T cell interleukin-12 responsiveness through the differential modulation of high-affinity interleukin-12 receptor expression. Eur J Immunol. 1997 Mar; 27(3):647-52.
View in:
PubMed
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res. 1997 Mar; 3(3):409-17.
View in:
PubMed
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J Clin Oncol. 1997 Feb; 15(2):723-34.
View in:
PubMed
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin Cancer Res. 1997 Jan; 3(1):17-24.
View in:
PubMed
TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. Blood. 1996 Dec 01; 88(11):4252-8.
View in:
PubMed
Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60.
View in:
PubMed
CD2-CD58 interaction and the control of T-cell interleukin-12 responsiveness. Adhesion molecules link innate and acquired immunity. Ann N Y Acad Sci. 1996 Oct 31; 795:71-81.
View in:
PubMed
High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6.
View in:
PubMed
Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35.
View in:
PubMed
Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2334-41.
View in:
PubMed
Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12. J Immunol. 1996 Sep 01; 157(5):1886-93.
View in:
PubMed
R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54.
View in:
PubMed
Sources and sequelae of bacterial contamination of hematopoietic stem cell components: implications for the safety of hematotherapy and graft engineering. Transfusion. 1996 Sep; 36(9):782-8.
View in:
PubMed
Transcript synthesis and surface expression of the interleukin-2 receptor (alpha-, beta-, and gamma-chain) by normal and malignant myeloid cells. Blood. 1996 Mar 15; 87(6):2419-27.
View in:
PubMed
Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar; 2(3):493-9.
View in:
PubMed
Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease. Am J Pathol. 1996 Mar; 148(3):847-53.
View in:
PubMed
Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression. Immunology. 1996 Mar; 87(3):402-7.
View in:
PubMed
Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia. Exp Hematol. 1996 Feb; 24(3):406-15.
View in:
PubMed
Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997; 15(5):213-26.
View in:
PubMed
Interleukin 12: Basic Biology and Potential Applications in Cancer Treatment. Oncologist. 1996; 1(1 & 2):88-97.
View in:
PubMed
Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells. Cell Immunol. 1995 Oct 15; 165(2):211-6.
View in:
PubMed
CD2 regulates responsiveness of activated T cells to interleukin 12. J Exp Med. 1995 Sep 01; 182(3):721-31.
View in:
PubMed
Interleukin 2 signaling involves the phosphorylation of Stat proteins. Proc Natl Acad Sci U S A. 1995 Aug 15; 92(17):7779-83.
View in:
PubMed
Functional consequences of APO-1/Fas (CD95) antigen expression by normal and neoplastic hematopoietic cells. Leuk Lymphoma. 1995 Mar; 17(1-2):51-61.
View in:
PubMed
Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93.
View in:
PubMed
Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15; 85(4):1132-7.
View in:
PubMed
Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. Blood. 1995 Feb 15; 85(4):925-8.
View in:
PubMed
Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol. 1995 Jan; 13(1):239-50.
View in:
PubMed
Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. J Clin Apher. 1995; 10(3):139-43.
View in:
PubMed
Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. J Clin Immunol. 1995 Jan; 15(1):51-7.
View in:
PubMed
Prevention of T cell anergy by signaling through the gamma c chain of the IL-2 receptor. Science. 1994 Nov 11; 266(5187):1039-42.
View in:
PubMed
Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Oct 01; 84(7):2109-14.
View in:
PubMed
Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest. 1994 Aug; 94(2):481-8.
View in:
PubMed
Alterations in Ca2+ signal transduction in critically ill surgical patients. Surgery. 1994 Aug; 116(2):378-86; discussion 386-7.
View in:
PubMed
Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994 Aug 01; 84(3):964-71.
View in:
PubMed
Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells. J Exp Med. 1994 Jul 01; 180(1):241-51.
View in:
PubMed
The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73.
View in:
PubMed
The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1994 Mar 15; 57(5):780.
View in:
PubMed
CD antigens 1993. Immunol Today. 1994 Mar; 15(3):98-9.
View in:
PubMed
CD antigens 1993. Blood. 1994 Feb 15; 83(4):879-80.
View in:
PubMed
Tumor immunity: will new keys unlock the door? J Clin Oncol. 1994 Feb; 12(2):237-8.
View in:
PubMed
Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Int J Cancer Suppl. 1994; 8:57-9.
View in:
PubMed
CD antigens 1993. J Immunol. 1994 Jan 01; 152(1):1-2.
View in:
PubMed
Preparation and characterization of interleukin-2-gelonin conjugates made using different cross-linking reagents. Bioconjug Chem. 1994 Jan-Feb; 5(1):88-97.
View in:
PubMed
Interleukin-12 induces tyrosine phosphorylation and activation of 44-kD mitogen-activated protein kinase in human T cells. Blood. 1994 Jan 01; 83(1):184-90.
View in:
PubMed
Prognostic significance of the surface antigens expressed by leukemic cells. Leuk Lymphoma. 1994; 13 Suppl 1:15-22.
View in:
PubMed
Use of CD33 monoclonal antibodies in bone marrow transplantation for acute myeloid leukemia. Prog Clin Biol Res. 1994; 389:47-63.
View in:
PubMed
Fc gamma RIIIA-mediated signaling involves src-family lck in human natural killer cells. J Immunol. 1993 Dec 15; 151(12):6794-800.
View in:
PubMed
Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993 Nov 01; 82(9):2790-6.
View in:
PubMed
Clinical significance of bcr-abl gene rearrangement detected by the polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Leuk Lymphoma. 1993 May; 10(1-2):1-8.
View in:
PubMed
Autologous bone marrow transplantation after a long first remission for children with recurrent acute lymphoblastic leukemia. Blood. 1993 Mar 15; 81(6):1651-7.
View in:
PubMed
Costimulatory signals are required for optimal proliferation of human natural killer cells. J Immunol. 1993 Mar 01; 150(5):1705-14.
View in:
PubMed
Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993; 12 Suppl 3:S7-10.
View in:
PubMed
Disruption of the SCL locus in T-lymphoid malignancies correlates with commitment to the T-cell receptor alpha beta lineage. Blood. 1992 Sep 15; 80(6):1511-20.
View in:
PubMed
Participation of the CD27 antigen in the regulation of IL-2-activated human natural killer cells. J Immunol. 1992 Aug 15; 149(4):1199-203.
View in:
PubMed
Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992 Mar 01; 175(3):779-88.
View in:
PubMed
Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore). 1992 Mar; 71(2):73-83.
View in:
PubMed
Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood. 1992 Feb 01; 79(3):576-85.
View in:
PubMed
Changing antigen receptor gene rearrangements in a case of early pre-B cell leukemia: evidence for a tumor progenitor cell with stem cell features and implications for monitoring residual disease. Blood. 1992 Jan 15; 79(2):481-8.
View in:
PubMed
Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992 Jan 15; 79(2):517-26.
View in:
PubMed
Differential responses to interleukin 2 define functionally distinct subsets of human natural killer cells. Eur J Immunol. 1992 Jan; 22(1):1-6.
View in:
PubMed
Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9.
View in:
PubMed
Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15; 78(10):2759-67.
View in:
PubMed
Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1991 Aug; 8(2):143-5.
View in:
PubMed
Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9.
View in:
PubMed
Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood. 1991 Jun 01; 77(11):2404-12.
View in:
PubMed
Monoclonal anti-T cell (T12) antibody treatment of graft-versus-host disease in severe combined immunodeficiency: targeting of antibody and activation of complement on CD8+ cytotoxic T cell surfaces. J Allergy Clin Immunol. 1991 May; 87(5):1029-33.
View in:
PubMed
Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation. 1991 Mar; 51(3):630-6.
View in:
PubMed
Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15; 77(4):712-20.
View in:
PubMed
Biology and clinical relevance of human natural killer cells. Blood. 1990 Dec 15; 76(12):2421-38.
View in:
PubMed
Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells. Cell Immunol. 1990 Dec; 131(2):352-65.
View in:
PubMed
Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990 Dec; 6(6):445-7.
View in:
PubMed
Human natural killer cell adhesion molecules. Differential expression after activation and participation in cytolysis. J Immunol. 1990 Nov 15; 145(10):3194-201.
View in:
PubMed
Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31.
View in:
PubMed
Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990 May 15; 75(10):2076-84.
View in:
PubMed
Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med. 1990 May 01; 171(5):1509-26.
View in:
PubMed
The evolving role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am. 1990 Apr; 4(2):369-88.
View in:
PubMed
Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc Natl Acad Sci U S A. 1990 Mar; 87(6):2274-8.
View in:
PubMed
Natural history of mixed chimerism after bone marrow transplantation with CD6-depleted allogeneic marrow: a stable equilibrium. Blood. 1990 Jan 01; 75(1):296-304.
View in:
PubMed
Comparative activities of rabbit complements of different ages using an in-vitro marrow purging model. Leuk Res. 1990; 14(5):407-16.
View in:
PubMed
Anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation for B-cell non-Hodgkin's lymphoma: phenotypic reconstitution and B-cell function. Blood. 1989 Nov 01; 74(6):2203-11.
View in:
PubMed
Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med. 1989 Oct 19; 321(16):1080-5.
View in:
PubMed
CD3-negative natural killer cells express zeta TCR as part of a novel molecular complex. Nature. 1989 Sep 14; 341(6238):159-62.
View in:
PubMed
Clonal evidence for the induction of NKH1 on activated human thymocytes. Functional changes associated with antigen expression. Eur J Immunol. 1989 Sep; 19(9):1735-9.
View in:
PubMed
The role of natural killer cells in immune surveillance. N Engl J Med. 1989 Jun 29; 320(26):1748-9.
View in:
PubMed
Activation of human cytolytic cells through CD2/T11. Comparison of the requirements for the induction and direction of lysis of tumor targets by T cells and NK cells. J Immunol. 1989 Jun 01; 142(11):4105-12.
View in:
PubMed
Mechanism of graft failure in HLA-matched and HLA-mismatched bone marrow transplant recipients. Bone Marrow Transplant. 1989 May; 4(3):239-45.
View in:
PubMed
Identification of carboxypeptidase and tryptic esterase activities that are complexed to proteoglycans in the secretory granules of human cloned natural killer cells. J Immunol. 1989 Jan 15; 142(2):609-15.
View in:
PubMed
Autologous bone marrow transplantation therapy for multiple myeloma. Eur J Haematol Suppl. 1989; 51:157-63.
View in:
PubMed
Identification of a second transforming gene, rasn, in a human multiple myeloma line with a rearranged c-myc allele. Blood. 1988 Oct; 72(4):1163-7.
View in:
PubMed
Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses. J Immunol. 1988 Jul 01; 141(1):131-8.
View in:
PubMed
Molecular cloning of the common acute lymphoblastic leukemia antigen (CALLA) identifies a type II integral membrane protein. Proc Natl Acad Sci U S A. 1988 Jul; 85(13):4819-23.
View in:
PubMed
Induction of natural killer effectors from human thymus with recombinant IL-2. J Immunol. 1988 May 15; 140(10):3660-7.
View in:
PubMed
T11/CD2 activation of cloned human natural killer cells results in increased conjugate formation and exocytosis of cytolytic granules. J Immunol. 1988 Feb 01; 140(3):991-1002.
View in:
PubMed
Characterization of functional surface structures on human natural killer cells. Adv Immunol. 1988; 42:181-211.
View in:
PubMed
Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement. Cancer Treat Res. 1988; 38:265-83.
View in:
PubMed
Phenotypic and functional deficiency of natural killer cells in patients with chronic fatigue syndrome. J Immunol. 1987 Nov 15; 139(10):3306-13.
View in:
PubMed
Lymphoma with clonal T-cell receptor gene rearrangement in a 25-year survivor of Hodgkin's disease. Cancer. 1987 Nov 01; 60(9):2213-8.
View in:
PubMed
Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with a poor prognosis. N Engl J Med. 1987 Jun 11; 316(24):1499-505.
View in:
PubMed
Identification and cloning of a prethymic precursor T lymphocyte from a population of common acute lymphoblastic leukemia antigen (CALLA)-positive fetal bone marrow cells. J Exp Med. 1987 Jun 01; 165(6):1749-54.
View in:
PubMed
Ultrastructural evidence that the granules of human natural killer cell clones store membrane in a nonbilayer phase. Am J Pathol. 1987 May; 127(2):305-16.
View in:
PubMed
Epstein-Barr virus-transformed B-cell line (DV-1) derived from bone marrow of a patient with severe combined immunodeficiency and immunoblastic lymphoma. Pediatr Res. 1987 Apr; 21(4):331-7.
View in:
PubMed
Hematologic engraftment and immune reconstitution posttransplantation with anti-B1 purged autologous bone marrow. Blood. 1987 Feb; 69(2):597-604.
View in:
PubMed
Monoclonal antibodies: their use in bone marrow transplantation. Prog Hematol. 1987; 15:137-81.
View in:
PubMed
Enhancement of natural killer function through activation of the T11 E rosette receptor. J Clin Invest. 1987 Jan; 79(1):305-8.
View in:
PubMed
Activation of natural killer function through the T11/E rosette receptor. Haematol Blood Transfus. 1987; 31:347-50.
View in:
PubMed
Monoclonal-antibody-purged autologous bone marrow transplantation for relapsed non-T-cell acute lymphoblastic leukemia in childhood. Haematol Blood Transfus. 1987; 31:67-74.
View in:
PubMed
In vitro regulation of human hematopoiesis by natural killer cells: analysis at a clonal level. Blood. 1987 Jan; 69(1):246-54.
View in:
PubMed
Function of the LFA-1 and T4 molecules in the direct activation of resting human B lymphocytes by T lymphocytes. Eur J Immunol. 1986 Dec; 16(12):1539-43.
View in:
PubMed
In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. Delivery of ribosome-inactivating proteins to spleen and lymph node T cells. J Clin Invest. 1986 Sep; 78(3):666-73.
View in:
PubMed
Characterization of antileukemia cells' cytotoxic effector function. Implications for monitoring natural killer responses following allogeneic bone marrow transplantation. Transplantation. 1986 Sep; 42(3):252-6.
View in:
PubMed
Use of highly polymorphic DNA probes for genotypic analysis following bone marrow transplantation. Blood. 1986 Aug; 68(2):378-85.
View in:
PubMed
A subset of natural killer cells in peripheral blood displays a mature T cell phenotype. J Exp Med. 1986 Jul 01; 164(1):351-6.
View in:
PubMed
Depletion of T cells from human bone marrow using monoclonal antibodies and rabbit complement. A quantitative and functional analysis. Transplantation. 1986 Jul; 42(1):73-80.
View in:
PubMed
Expression of the NKTa clonotype in a series of human natural killer clones with identical cytotoxic specificity. J Exp Med. 1986 Apr 01; 163(4):812-25.
View in:
PubMed
In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates. In vivo stability of disulfide-linked immunotoxin conjugates. J Clin Invest. 1986 Mar; 77(3):977-84.
View in:
PubMed
Characterization of natural killer cells with antileukemia activity following allogeneic bone marrow transplantation. Blood. 1986 Mar; 67(3):722-8.
View in:
PubMed
Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody:ricin A chain conjugates. Cancer Res. 1986 Mar; 46(3):1208-13.
View in:
PubMed
Expression of the common acute lymphoblastic leukemia antigen (CALLA) on the surface of individual cells of human lymphoblastoid lines. J Immunol. 1986 Jan; 136(1):320-5.
View in:
PubMed
Antigenic heterogeneity among Burkitt's lymphoma cells surviving treatment with monoclonal antibody and complement. Leuk Res. 1986; 10(1):35-42.
View in:
PubMed
Functional surface structures on human natural killer cells. Klin Wochenschr. 1985 Dec 02; 63(23):1189-200.
View in:
PubMed
Proteoglycans in cell-mediated cytotoxicity. Identification, localization, and exocytosis of a chondroitin sulfate proteoglycan from human cloned natural killer cells during target cell lysis. J Exp Med. 1985 Dec 01; 162(6):1771-87.
View in:
PubMed
Specific release of proteoglycans from human natural killer cells during target lysis. Nature. 1985 Nov 21-27; 318(6043):289-91.
View in:
PubMed
Activation of cytolytic T lymphocyte and natural killer cell function through the T11 sheep erythrocyte binding protein. Nature. 1985 Oct 3-9; 317(6036):428-30.
View in:
PubMed
In vivo administration of lymphocyte-specific monoclonal antibodies in nonhuman primates: I. Effects of anti-T11 antibodies on the circulating T cell pool. Blood. 1985 Oct; 66(4):961-6.
View in:
PubMed
Activation of a novel human transforming gene, ret, by DNA rearrangement. Cell. 1985 Sep; 42(2):581-8.
View in:
PubMed
Orderly expression of B cell antigens during the in vitro differentiation of nonmalignant human pre-B cells. J Immunol. 1985 Sep; 135(3):1746-51.
View in:
PubMed
Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells. J Immunol. 1985 Aug; 135(2):1020-5.
View in:
PubMed
The role of interleukin 2 and T11 E rosette antigen in activation and proliferation of human NK clones. J Immunol. 1985 Jul; 135(1):672-8.
View in:
PubMed
Analysis of T-cell receptor gene rearrangement and expression in human natural killer clones. Science. 1985 Jun 28; 228(4707):1540-3.
View in:
PubMed
Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12-year-old patient with severe combined immunodeficiency. N Engl J Med. 1985 May 02; 312(18):1151-9.
View in:
PubMed
Elimination of clonogenic Burkitt's lymphoma cells from human bone marrow using 4-hydroperoxycyclophosphamide in combination with monoclonal antibodies and complement. Blood. 1985 May; 65(5):1064-70.
View in:
PubMed
Generation of monoclonal antibodies to a human natural killer clone. Characterization of two natural killer-associated antigens, NKH1A and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest. 1985 Mar; 75(3):932-43.
View in:
PubMed
Effects of monoclonal antibody and complement treatment of human marrow on hematopoiesis in continuous bone marrow culture. Cancer Res. 1985 Feb; 45(2):758-67.
View in:
PubMed
Elimination of malignant clonogenic cells from human bone marrow using multiple monoclonal antibodies and complement. Cancer Res. 1985 Feb; 45(2):499-503.
View in:
PubMed
Purification of common acute lymphoblastic leukemia antigen positive cells from normal human bone marrow. Blood. 1984 Sep; 64(3):662-6.
View in:
PubMed
Identification of a 140-kDa activation antigen as a target structure for a series of human cloned natural killer cell lines. Eur J Immunol. 1984 Sep; 14(9):844-52.
View in:
PubMed
Natural killer-like function of activated T lymphocytes: differential blocking effects of monoclonal antibodies specific for a 90-kDa clonotypic structure. Cell Immunol. 1984 Jul; 86(2):381-92.
View in:
PubMed
Clinical applications of monoclonal antibodies in acute leukemia. Ann N Y Acad Sci. 1984; 428:308-17.
View in:
PubMed
Identification of a clonally restricted 90 kD heterodimer on two human cloned natural killer cell lines. Its role in cytotoxic effector function. J Exp Med. 1983 Nov 01; 158(5):1547-60.
View in:
PubMed
Use of monoclonal antibodies in autologous and allogeneic bone marrow transplantation. Clin Haematol. 1983 Oct; 12(3):813-32.
View in:
PubMed
Identification and molecular cloning of the human Blym transforming gene activated in Burkitt's lymphomas. Nature. 1983 Sep 8-14; 305(5930):112-6.
View in:
PubMed
Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning. 1983 Apr; 1(1):33-48.
View in:
PubMed
Selective expression of the common acute lymphoblastic leukemia (gp 100) antigen on immature lymphoid cells and their malignant counterparts. Blood. 1983 Apr; 61(4):628-39.
View in:
PubMed
Establishment of a Ph1-positive human cell line (BV173). J Natl Cancer Inst. 1983 Mar; 70(3):447-53.
View in:
PubMed
Elimination of leukemic cells from human bone marrow using monoclonal antibody and complement. Cancer Res. 1983 Mar; 43(3):1389-94.
View in:
PubMed
Phenotypic and functional heterogeneity of human cloned natural killer cell lines. Nature. 1983 Jan 13; 301(5896):158-60.
View in:
PubMed
Interferon-induced changes in expression of antigens defined by monoclonal antibodies on malignant and nonmalignant mononuclear hematopoietic cells. J Interferon Res. 1983; 3(2):199-210.
View in:
PubMed
In vitro treatment with monoclonal antibody prior to autologous bone marrow transplantation in acute lymphoblastic leukemia. Haematol Blood Transfus. 1983; 28:117-23.
View in:
PubMed
Differentiation patterns in the blastic phase of chronic myeloid leukemia. Blood. 1983 Jan; 61(1):85-91.
View in:
PubMed
Purification and characterization of fetal hematopoietic cells that express the common acute lymphoblastic leukemia antigen (CALLA). J Exp Med. 1983 Jan 01; 157(1):114-29.
View in:
PubMed
Generation of a cloned NK cell line derived from the "null cell" fraction of human peripheral blood. J Immunol. 1982 Sep; 129(3):1299-305.
View in:
PubMed
Induction of human B cell antigens in non-T cell acute lymphoblastic leukemia. J Clin Invest. 1982 Aug; 70(2):433-42.
View in:
PubMed
Autologous bone-marrow transplantation in CALLA-positive acute lymphoblastic leukemia after in-vitro treatment with J5 monoclonal antibody and complement. Lancet. 1982 Jul 10; 2(8289):60-3.
View in:
PubMed
Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res. 1982 Feb; 42(2):457-64.
View in:
PubMed
Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood. 1982 Jan; 59(1):1-11.
View in:
PubMed
Use of monoclonal antibodies as diagnostic and therapeutic reagents in acute lymphoblastic leukemia. Cancer Res. 1981 Nov; 41(11 Pt 2):4771-5.
View in:
PubMed
Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol. 1981 Nov; 3(3):247-59.
View in:
PubMed
Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest. 1981 Oct; 68(4):932-41.
View in:
PubMed
Expression of a 26,000-dalton glycoprotein on activated human T cells. Cell Immunol. 1981 Oct; 64(1):192-9.
View in:
PubMed
Expression of common acute lymphoblastic leukemia antigen (CALLA) by lymphomas of B-cell and T-cell lineage. Blood. 1981 Sep; 58(3):648-52.
View in:
PubMed
Human cell lines express multiple populations of Ia-like molecules. Hum Immunol. 1981 Aug; 3(1):67-76.
View in:
PubMed
Absence of common ALL antigen on normal bipotent myeloid, erythroid, and granulocyte progenitors. Blood. 1981 Aug; 58(2):333-6.
View in:
PubMed
Serotherapy of acute lymphoblastic leukemia with monoclonal antibody. Blood. 1981 Jul; 58(1):141-52.
View in:
PubMed
Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood. 1981 Jun; 57(6):1105-10.
View in:
PubMed
Surface antigens on malignant Sézary and T-CLL cells correspond to those of mature T cells. Blood. 1981 Mar; 57(3):526-30.
View in:
PubMed
Fate of a common acute lymphoblastic leukemia antigen during modulation by monoclonal antibody. J Immunol. 1981 Feb; 126(2):540-4.
View in:
PubMed
Comparative antigenic phenotypes of normal and leukemic hemopoietic precursor cells analysed with a "library" of monoclonal antibodies. Haematol Blood Transfus. 1981; 26:296-304.
View in:
PubMed
Expression of normal monocyte-macrophage differentiation antigens on HL60 promyelocytes undergoing differentiation induced by leukocyte-conditioned medium or phorbol diester. Leuk Res. 1981; 5(6):491-5.
View in:
PubMed
A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981 Jan; 67(1):134-40.
View in:
PubMed
Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol. 1981; 12:187-225.
View in:
PubMed
Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro. J Immunol. 1980 Oct; 125(4):1506-14.
View in:
PubMed
Human leukemia-associated antigen: relation to a family of surface glycoproteins. J Immunol. 1980 Jun; 124(6):2794-9.
View in:
PubMed
Cell surface antigens: prognostic implications in childhood acute lymphoblastic leukemia. Blood. 1980 Mar; 55(3):395-402.
View in:
PubMed
A monoclonal antibody to human acute lymphoblastic leukaemia antigen. Nature. 1980 Feb 07; 283(5747):583-5.
View in:
PubMed
Leukemia-associated antigens in ALL. Blood. 1979 Dec; 54(6):1240-8.
View in:
PubMed
Ia determinants on human T-cell subsets defined by monoclonal antibody. Activation stimuli required for expression. J Exp Med. 1979 Dec 01; 150(6):1472-82.
View in:
PubMed
Systemic mastocytosis associated with presence of rheumatoid factor. JAMA. 1976 Apr 12; 235(15):1586-7.
View in:
PubMed